Hypogonadotropic Hypogonadism - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 56 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hypogonadotropic Hypogonadism - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hypogonadotropic Hypogonadism - Pipeline Review, H2 2014', provides an overview of the Hypogonadotropic Hypogonadism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypogonadotropic Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypogonadotropic Hypogonadism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypogonadotropic Hypogonadism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hypogonadotropic Hypogonadism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hypogonadotropic Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypogonadotropic Hypogonadism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypogonadotropic Hypogonadism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypogonadotropic Hypogonadism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypogonadotropic Hypogonadism Overview 6
Therapeutics Development 7
Pipeline Products for Hypogonadotropic Hypogonadism - Overview 7
Pipeline Products for Hypogonadotropic Hypogonadism - Comparative Analysis 8
Hypogonadotropic Hypogonadism - Therapeutics under Development by Companies 9
Hypogonadotropic Hypogonadism - Therapeutics under Investigation by Universities/Institutes 10
Hypogonadotropic Hypogonadism - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Hypogonadotropic Hypogonadism - Products under Development by Companies 14
Hypogonadotropic Hypogonadism - Products under Investigation by Universities/Institutes 15
Hypogonadotropic Hypogonadism - Companies Involved in Therapeutics Development 16
Merck & Co., Inc. 16
Novartis AG 17
Repros Therapeutics Inc. 18
AlphaMab Co., Ltd 19
Hypogonadotropic Hypogonadism - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
enclomiphene - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
corifollitropin alfa - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BGS-649 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Kisspeptin-10 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
follitropin alfa - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Hypogonadotropic Hypogonadism - Recent Pipeline Updates 36
Hypogonadotropic Hypogonadism - Product Development Milestones 47
Featured News & Press Releases 47
Jul 16, 2014: FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal Versus Approved Topical Gel and Placebo 47
May 13, 2014: Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel 47
Apr 30, 2014: FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal Versus Approved Topical Gel 48
Apr 14, 2014: Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal Versus the Leading Topical Testosterone Gel 49
Mar 19, 2014: Ferring Pharmaceuticals Receives FDA Approval for the First and Only Mixed Protocol IVF Treatment - Combines MENOPUR (menotropins for injection) and BRAVELLE (urofollitropin for injection, purified) in Single Syringe 50
Jan 08, 2014: Repros Initiates Two Head to Head Studies of Androxal Versus the Leading Topical Testosterone Gel 51
Dec 04, 2013: Auxilium Pharmaceuticals Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment 51
Nov 25, 2013: FDA Schedules Face to Face Meeting With Repros to Discuss Androxal Efficacy 52
Nov 25, 2013: Repros to Present Data on the Benefits of Testosterone Restoration With Androxal Compared to T Replacement With Gels at 9th Men's Health World Congress 52
Oct 22, 2013: Repros Receives FDA Guidance For Androxal Clinical Program 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Number of Products under Development for Hypogonadotropic Hypogonadism, H2 2014 7
Number of Products under Development for Hypogonadotropic Hypogonadism - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Hypogonadotropic Hypogonadism - Pipeline by Merck & Co., Inc., H2 2014 16
Hypogonadotropic Hypogonadism - Pipeline by Novartis AG, H2 2014 17
Hypogonadotropic Hypogonadism - Pipeline by Repros Therapeutics Inc., H2 2014 18
Hypogonadotropic Hypogonadism - Pipeline by AlphaMab Co., Ltd, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Hypogonadotropic Hypogonadism Therapeutics - Recent Pipeline Updates, H2 2014 36